These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29911568)

  • 1. [France in the European cooperation for the technological evaluation of health products].
    Meyer F
    Med Sci (Paris); 2018 May; 34 Hors série n°1():57-59. PubMed ID: 29911568
    [No Abstract]   [Full Text] [Related]  

  • 2. [Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France].
    Bélorgey C
    Med Sci (Paris); 2018 May; 34 Hors série n°1():49-50. PubMed ID: 29911564
    [No Abstract]   [Full Text] [Related]  

  • 3. [Appraisal of medicinal products by the French CEPS].
    Planel MP
    Med Sci (Paris); 2018 May; 34 Hors série n°1():50-51. PubMed ID: 29911565
    [No Abstract]   [Full Text] [Related]  

  • 4. [Editorial Letter. Drug approval].
    Borvendég J
    Neuropsychopharmacol Hung; 2011 Jun; 13(2):54-5. PubMed ID: 21919287
    [No Abstract]   [Full Text] [Related]  

  • 5. New modalities of prescription of ATUns: Evolutions and revolution.
    Vignot S; Plaine G; Chapel E
    Rev Neurol (Paris); 2020 May; 176(4):290-292. PubMed ID: 31611006
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 7. Rent increase hits Europe's drug regulator before Brexit move.
    Vesper I
    Nature; 2018 Apr; 556(7702):418. PubMed ID: 29691518
    [No Abstract]   [Full Text] [Related]  

  • 8. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An institutional point of view - From label to delivery of an innovative treatment: what a journey! (4)].
    Belcastro J
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():39-41. PubMed ID: 30943162
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [France in the European and International research landscape].
    Julkowska D
    Med Sci (Paris); 2018 May; 34 Hors série n°1():55-57. PubMed ID: 29911567
    [No Abstract]   [Full Text] [Related]  

  • 12. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. France is set to radically overhaul its drug regulatory system.
    Arie S
    BMJ; 2011 Aug; 343():d4979. PubMed ID: 21816751
    [No Abstract]   [Full Text] [Related]  

  • 15. A tribute to the foot soldiers: European health agencies in the fight against antimicrobial resistance.
    Deruelle T
    Health Econ Policy Law; 2021 Jan; 16(1):23-37. PubMed ID: 32727635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new colonialism?--Conducting clinical trials in India.
    Nundy S; Gulhati CM
    N Engl J Med; 2005 Apr; 352(16):1633-6. PubMed ID: 15843665
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC).
    Fujiwara Y; Kobayashi K
    Crit Rev Oncol Hematol; 2002 May; 42(2):145-55. PubMed ID: 12007972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 19. New submissions adding to federal government's drug-approval backlog.
    Rafuse J
    CMAJ; 1991 Feb; 144(4):486-7. PubMed ID: 1993299
    [No Abstract]   [Full Text] [Related]  

  • 20. Members need only apply.
    Nat Biotechnol; 2011 Jul; 29(7):551. PubMed ID: 21747362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.